AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
129 hedge funds and large institutions have $1.35B invested in Aimmune Therapeutics in 2017 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
70% less call options, than puts
Call options by funds: $2.56M | Put options by funds: $8.4M
Holders
129
Holding in Top 10
8
Calls
$2.56M
Puts
$8.4M
Top Buyers
| 1 | +$43M | |
| 2 | +$27.7M | |
| 3 | +$18.7M | |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$11.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| 1 | -$35.3M | |
| 2 | -$28.4M | |
| 3 | -$27.2M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.3M |